Purpose: Behavioral data collected from smartphones can assist artificial intelligence (AI) in assessing and predicting fluctuations in mental states in patients with bipolar disorder (BD). In Poland, the MoodMon online system is used to integrate passive and active data, including voice parameters, for analysis and the issue of alerts based on changes in individual's mental state. The study aims to explore whether active engagement of the patient enhances the efficacy of the advanced MoodMon tool. This clinical trial is embedded in a broader research initiative.
Methods: Methodologically, smartphones were used to automatically collect daily activity data from wristbands and phones of 75 BD patients. Clinical evaluations, using the Hamilton Depression and Young Mania Rating Scales were conducted via a web app, regular visits, calls, or system-initiated contacts after alerts. The MoodMon system, trained on patient data, was compared against clinical evaluations, successfully predicting mental states.
Results: Results showed high alert accuracy: true positive ratio (TPR) at 86.6% (sensitivity) and true negative ratio (TNR) at 98.59% (specificity). Active patient voice data submissions notably improved the prediction of changes or stability in mental states.
Conclusions: Active patient participation in data submission enhances MoodMon's effectiveness as an AI-driven monitoring tool for BD. This underscores the potential of behavioral markers and mobile health applications in mental health care.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11891757 | PMC |
http://dx.doi.org/10.5114/ppn.2024.147100 | DOI Listing |
JAMA Psychiatry
March 2025
Institute of Behavioral Science, Feinstein Institutes for Medical Research, Manhasset, New York.
Importance: Peripheral (blood-based) biomarkers for psychiatric illness could benefit diagnosis and treatment, but research to date has typically been low throughput, and traditional case-control studies are subject to potential confounds of treatment and other exposures. Large-scale 2-sample mendelian randomization (MR) can examine the potentially causal impact of circulating proteins on neuropsychiatric phenotypes without these confounds.
Objective: To identify circulating proteins associated with risk for schizophrenia (SCZ), bipolar disorder (BD), and major depressive disorder (MDD) as well as cognitive task performance (CTP).
Aging Dis
March 2025
First Clinical Medical College, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
Recent advances in microbial pathogen research have highlighted the potential of gut microbe-based microbial medicine. One of the most extensively studied biological pathways is the gut-brain axis, which has been shown to reverse neurological disorders. Evidence from animal-based studies of dysbiosis suggest complex behavioral changes, such as alterations in sociability and anxiety, can be modulated through gut microbiota.
View Article and Find Full Text PDFEpilepsia
March 2025
Department of Clinical Biochemistry, Holbæk Hospital, Holbæk, Denmark.
Objective: The aim of the study is to provide insight into the real-world use of therapeutic drug monitoring (TDM) for the most common antiseizure medications (ASMs).
Methods: In total, 137 586 samples from the period 2019-2023 were collected from the five main Danish laboratories performing TDM. A previously described algorithm developed to exclude abnormal TDM results from patient data was applied.
Psychol Med
March 2025
Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Background: Sustained attention is integral to goal-directed tasks in everyday life. It is a demanding and effortful process prone to failure. Deficits are particularly prevalent in mood disorders.
View Article and Find Full Text PDFCureus
February 2025
Psychiatry, Hatsuishi Hospital, Kashiwa, JPN.
Corticosteroid treatment sometimes causes psychiatric side effects such as mania, depression, and psychosis. It is believed that exogenous corticosteroids lead to dysregulation of corticosteroid signaling and neurotransmitters in a dose-dependent manner. Therefore, the administration of corticosteroids is at risk of worsening bipolar disorder.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!